Analysts Trim Celldex Price Targets, Shares Fall

Celldex Therapeutics faces a flurry of analyst revisions, with Cantor Fitzgerald and Canaccord Genuity trimming targets to 61 and 60 while maintaining overweight/buy ratings, and Morgan Stanley lowering its target to 40, reflecting mixed sentiment. Meanwhile, firms like Guggenheim and Wells Fargo have raised targets to around 100 and 54 respectively, indicating a broad range of views on the stock’s near-term prospects as it trades in the mid-30s.